A Phase 4 interventional study of Esomeprazole and Lansoprazole in Erosive Esophagitis, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-03-26.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing esomeprazole in Heartburn — none open to participants now, none under way, none of them phase 3. Esomeprazole · Heartburn.
Among the 19 studies testing esomeprazole in Heartburn, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2002, is one of 15 in phase 4, and was the 11th registered.
154 studies on the registry are indexed under Heartburn; 12 are open to participants now.
Browse Heartburn studies →None of the 19 studies testing esomeprazole in Heartburn is open now. The open studies under Heartburn, anywhere →
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 8 Heartburn studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2002.
This study's planned enrollment of 1,000 is above the median of 100 across 127 interventional studies indexed under Heartburn.
Median enrollment 248 across the 19 interventional studies. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 5 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
24 studies in Heartburn by AstraZeneca: none open now, none under way, none of them phase 3. Of 24 finished, 8 (33%) have results posted.
Among the 24 studies in Heartburn by AstraZeneca, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2002, is one of 12 in phase 4, and was the 13th registered.
AstraZeneca’s Heartburn studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing esomeprazole in Heartburn, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 24 in Heartburn:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study looks at the healing rates in patients with Erosive Esophagitis (EE) when treated with either esomeprazole or lansoprazole
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Nexium
Drug: Esomeprazole
Prevacid
Drug: Lansoprazole
40mg once daily
Also known as: Nexium
30mg once daily
Also known as: Prevacid
To compare the difference in healing rates of erosive esophagitis (EE) between esomeprazole 40 mg qd (E40) and lansoprazole 30 mg qd (L30) in patients with moderate or severe EE, defined as Grade C or D in the Los Angeles (LA) Classification scale.
Time frame: Esophagogastroduodenoscopy (EGD) at baseline and then week 4 and week 8 (if not healed at week 4)
1. To compare the difference in the resolution of, and relief of, the investigator evaluated GERD symptoms of heartburn, acid regurgitation, dysphagia, and epigastric pain between E40 and L30 at week 4 of treatment in patients with moderate or severe EE.
Time frame: Esophagogastroduodenoscopy (EGD) at baseline and then week 4 and week 8 (if not healed at week 4)
1. To compare the difference between E40 and L30 in the occurrence of heartburn symptoms as reported in the patient's daily diary.
Time frame: Dairy card to be completed by patient daily
To evaluate safety and tolerability of E40 compared to that of L30 in patients with moderate or severe EE.
Time frame: Adverse event collection on an ongoing basis
No study locations are listed for this record.
The record gives a start of Dec 2002, a primary completion of Aug 2003 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole